-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The R&D pipeline is growing steadily.
As of April 16, 2021, there are 2,073 live cell therapy drugs under development worldwide, 572 more than the number updated before 2020, with a growth rate of 38%
.
Among different types of cell therapy, CAR-T cell therapy continues to dominate the R&D pipeline with 299 new Chinese medicines added to the pipeline, an increase of 35% over 2020
.
Most CAR-T cell therapies (80%) are in the preclinical and phase I stages
.
80 new drugs have been added to T cell receptor (TCR) therapy, followed by NK/NKT cells and new T cells
.
Most cell therapies are of autologous origin, and the autologous preparations under development are twice the allogeneic preparations
.
In the past year, the number of allogeneic drugs in preclinical and clinical phase I development has increased significantly (48% and 42%, respectively), while growth rates in 2020 are 80% and 95%, respectively
.
However, compared with last year, the number of allogeneic cell therapy drugs in Phase II development has increased even more
.
Nature Reviews | Drug Discovery The main targets of cell therapy drugs Among the targets of all cell therapy drugs, CD19, BCMA and CD22 are still the main targets for hematological indications, and compared with the sharp increase in the previous year, in the past year The number of drugs for these targets has increased appropriately (15%, 23%, and 56%)
.
The reasons behind the year-on-year decline in the number of drugs for these targets may include market saturation and the impact of COVID-19 on drug development
.
In terms of solid tumors, the popular targets for research and development remain basically unchanged, and the undisclosed tumor-associated antigen (TAA) is also among the best
.
Most solid tumor drugs use CAR-T cell enhancement mode to overcome the challenges related to recognition, transport and survival in the tumor microenvironment
.
It is worth noting that the development of cell therapy drugs targeting GPC2 and GPC3 continues its rapid growth, which has almost doubled every year since 2019, and its market potential in liver cancer is vast
.
Overview of cell therapy trials According to the statistics of ClinicalTrials.
gov, it is found that as of April 2021, there are a total of 1,358 active cell therapy trials.
The growth rate from 2020 to 2021 is 24%, and most of the growth is due to CAR-T cells.
Clinical trials and other cell therapies
.
Similar to the past, most trials focused on hematological malignancies, 40% of trials targeted solid tumors, most of which are in the early stages, which may also reflect the inherent challenges of using cell therapy to treat solid tumors
.
At the same time, when observing the research centers of these cell therapy trials, it was found that all the top hospitals and universities conducting cell therapy trials are located in the United States, indicating that despite the global interest in cell therapy, the United States is still the leader in trial management
.
Global R&D pipeline distribution The United States and China continue to dominate the cell therapy pipeline, accounting for 791 and 695 respectively
.
The distribution of cell therapy research and development in the United States and China is roughly the same as the previous year: most drugs in the United States (83%) are developed in pharmaceutical companies, while the distribution in China is more even (60% pharmaceutical companies and 40% academic)
.
Our current analysis shows that the clinical development of cell therapies continues, albeit at a slower pace compared to previous years
.
Although clinical trials of cell therapy are accumulating, real-world data show that the number of patients receiving cell therapy in clinical practice is decreasing, especially at the peak of the 2020 pandemic
.
With the stabilization of COVID-19 cases and the evolution of the clinical, social and economic landscape, we are seeing a refurbishment of the number of cell therapy trials that are being launched
.
In view of the continuous improvement of COVID-19 management and continuous innovation in the field of tumor cell therapy, the prospect of cell therapy still exists
.
Reference source: doi: https://doi.
org/10.
1038/d41573-021-00100-z Copyright statement welcome personal forwarding and sharing
.
Any other media or website that needs to reprint or quote the copyrighted content of this website must obtain authorization and indicate "Reposted from: Aogu" in a prominent position
.
As of April 16, 2021, there are 2,073 live cell therapy drugs under development worldwide, 572 more than the number updated before 2020, with a growth rate of 38%
.
Among different types of cell therapy, CAR-T cell therapy continues to dominate the R&D pipeline with 299 new Chinese medicines added to the pipeline, an increase of 35% over 2020
.
Most CAR-T cell therapies (80%) are in the preclinical and phase I stages
.
80 new drugs have been added to T cell receptor (TCR) therapy, followed by NK/NKT cells and new T cells
.
Most cell therapies are of autologous origin, and the autologous preparations under development are twice the allogeneic preparations
.
In the past year, the number of allogeneic drugs in preclinical and clinical phase I development has increased significantly (48% and 42%, respectively), while growth rates in 2020 are 80% and 95%, respectively
.
However, compared with last year, the number of allogeneic cell therapy drugs in Phase II development has increased even more
.
Nature Reviews | Drug Discovery The main targets of cell therapy drugs Among the targets of all cell therapy drugs, CD19, BCMA and CD22 are still the main targets for hematological indications, and compared with the sharp increase in the previous year, in the past year The number of drugs for these targets has increased appropriately (15%, 23%, and 56%)
.
The reasons behind the year-on-year decline in the number of drugs for these targets may include market saturation and the impact of COVID-19 on drug development
.
In terms of solid tumors, the popular targets for research and development remain basically unchanged, and the undisclosed tumor-associated antigen (TAA) is also among the best
.
Most solid tumor drugs use CAR-T cell enhancement mode to overcome the challenges related to recognition, transport and survival in the tumor microenvironment
.
It is worth noting that the development of cell therapy drugs targeting GPC2 and GPC3 continues its rapid growth, which has almost doubled every year since 2019, and its market potential in liver cancer is vast
.
Overview of cell therapy trials According to the statistics of ClinicalTrials.
gov, it is found that as of April 2021, there are a total of 1,358 active cell therapy trials.
The growth rate from 2020 to 2021 is 24%, and most of the growth is due to CAR-T cells.
Clinical trials and other cell therapies
.
Similar to the past, most trials focused on hematological malignancies, 40% of trials targeted solid tumors, most of which are in the early stages, which may also reflect the inherent challenges of using cell therapy to treat solid tumors
.
At the same time, when observing the research centers of these cell therapy trials, it was found that all the top hospitals and universities conducting cell therapy trials are located in the United States, indicating that despite the global interest in cell therapy, the United States is still the leader in trial management
.
Global R&D pipeline distribution The United States and China continue to dominate the cell therapy pipeline, accounting for 791 and 695 respectively
.
The distribution of cell therapy research and development in the United States and China is roughly the same as the previous year: most drugs in the United States (83%) are developed in pharmaceutical companies, while the distribution in China is more even (60% pharmaceutical companies and 40% academic)
.
Our current analysis shows that the clinical development of cell therapies continues, albeit at a slower pace compared to previous years
.
Although clinical trials of cell therapy are accumulating, real-world data show that the number of patients receiving cell therapy in clinical practice is decreasing, especially at the peak of the 2020 pandemic
.
With the stabilization of COVID-19 cases and the evolution of the clinical, social and economic landscape, we are seeing a refurbishment of the number of cell therapy trials that are being launched
.
In view of the continuous improvement of COVID-19 management and continuous innovation in the field of tumor cell therapy, the prospect of cell therapy still exists
.
Reference source: doi: https://doi.
org/10.
1038/d41573-021-00100-z Copyright statement welcome personal forwarding and sharing
.
Any other media or website that needs to reprint or quote the copyrighted content of this website must obtain authorization and indicate "Reposted from: Aogu" in a prominent position
.
